This study examines the cost-effectiveness of SSRIs as compared toTCAs in the outpatient treatment of depression. It assesses whether SSRIs, with their higher price, have the ability to enhance the success of antidepressive treatments, can lead to savings in other health care expenditures and can improve quality of life for patients.